FDA approves Novartis’ Egaten to treat fascioliasis

This article was originally published here

Egaten is claimed to be the only FDA-approved drug to treat fascioliasis, which is a neglected tropical disease. Fascioliasis, which is commonly known as liver fluke infestation, is

The post FDA approves Novartis’ Egaten to treat fascioliasis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply